依托泊苷+洛铂+安罗替尼+信迪利单抗一线治疗ES-SCLC的疗效评价及生存分析

Efficacy evaluation and survival analysis of etoposide+lobaplatin+anlotinib+sintilimab firstline treatment for extensive-stage small-cell lung cancer

目的探讨免疫检查点抑制剂联合抗血管生成治疗、联合化疗一线治疗广泛期小细胞肺癌(ESSCLC)的疗效评价及生存分析。方法选取2020年6月至2021年6月就诊于内蒙古自治区人民医院肿瘤内科的30例ES-SCLC患者为研究对象,对其进行依托泊苷+洛铂+安罗替尼+信迪利单抗一线治疗,评估其疗效、生活质量改善及不良反应。结果随访至2023年8月,中位总生存(OS)时间为17.3(15.1,19.4)个月,1年OS率为83.3%(95%CI:64.3%~94.1%)。中位无进展生存(PFS)时间为8.7(6.4,12.1)个月,完全缓解(CR)1例,部分缓解(PR)24例,疾病稳定(SD)3例,疾病进展(PD)2例,客观缓解率(ORR)为83.3%,疾病控制率(DCR)为93.3%。23例(76.7%)患者出现不同的不良反应,未发生3级及以上不良反应。结论依托泊苷+洛铂+安罗替尼+信迪利单抗一线治疗方案明显延长了ES-SCLC患者中位OS、PFS时间,且不良反应可控。

Objective To explore the effectiveness evaluation and survival analysis of immune checkpoint inhibitors combined with anti-angiogenic therapy and chemotherapy as first-line treatment for extensivestage small-cell lung cancer(ES-SCLC).Methods Thirty cases of EC-SCLC treated in department of Oncology,Inner Mongolia Autonomous Region People’s Hospital from June 2020 to June 2021 were selected as the study subjects and treated by etoposide+lobaplatin+anlotinib+sintilimab firstline treatment,the therapeutic effect,improvement of living quality and adverse reactions were evaluated.Results The follow up was until August 2023.The median overall survival(OS)time was 17.3(15.1,19.4)months,the 1 year OS rate was 83.3%(95%CI:64.3%-94.1%).The median progression-free(PFS)time was 8.7(6.4,12.1)months,there was 1 case of complete remission(CR),24 cases of partial remission(PR),3 cases of stable disease(SD)and 2 cases of progress of disease(PD),the objective remission rate(ORR)was 83.3%,the disease control rate(DCR)was 93.3%.Twenty-three cases(76.7%)developed different adverse reactions without more than grade three or above adverse reactions occurrence.Conclusion The etoposide+lobaplatin+anlotinib+sintilimab firstline treatment regimen obviously prolong median OS and PFS durations,moreover the adverse reactions are controlled.